Capricor Therapeutics (CAPR) Current Deferred Revenue (2014 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Current Deferred Revenue of $12.0 million for Q1 2026, little changed year-over-year from $12.0 million in Q1 2025, and little changed quarter-over-quarter from $12.0 million in Q4 2025.
Capricor Therapeutics (CAPR) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Capricor Therapeutics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $12.0 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue changed 0.0% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (changed 0.0% YoY), while the FY2025 annual figure was $12.0 million, changed 0.0% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $12.0 million, roughly flat from $12.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $40.0 million in Q1 2022, with the low at $12.0 million in Q4 2024.
- The 5-year median for Current Deferred Revenue is $15.7 million (2022), against an average of $19.0 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue jumped 86.16% in 2023, then sank 50.56% in 2024.
- Capricor Therapeutics' Current Deferred Revenue stood at $18.0 million in 2022, then soared by 34.98% to $24.3 million in 2023, then sank by 50.56% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
- Business Quant data shows CAPR's Current Deferred Revenue at $12.0 million in Q1 2026, $12.0 million in Q4 2025, and $12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | 12.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Jun 30, 2025 | 12.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Dec 31, 2024 | 12.00 Mn |
| Sep 30, 2024 | 13.13 Mn |
| Jun 30, 2024 | 15.39 Mn |
| Mar 31, 2024 | 19.36 Mn |
| Dec 31, 2023 | 24.27 Mn |
| Sep 30, 2023 | 25.41 Mn |
| Jun 30, 2023 | 29.31 Mn |
| Mar 31, 2023 | 31.01 Mn |
| Dec 31, 2022 | 17.98 Mn |
| Sep 30, 2022 | 18.60 Mn |
| Jun 30, 2022 | 15.75 Mn |
| Mar 31, 2022 | 40.00 Mn |
| Mar 31, 2017 | 683,592.00 |
| Dec 31, 2016 | 1.37 Mn |
| Sep 30, 2016 | 2.05 Mn |